YD Bio Limited YDES 深 沪
等待开盘 02-07 09:30:00 美东时间
11.52
+0.760
+7.06%
华盛通- 最 高11.63
- 今 开10.80
- 成交量 3.50万股
- 最 低 10.80
- 昨 收 10.76
- 总市值 8.12亿
- 52周最高 25.00
- 市盈率 静 --
- 换手率 0.05%
- 52周最低 7.20
- 委 比 -81.82%
- 总股本 7052.14万
- 历史最高 25.00
- 量 比 0.97
- 振 幅 7.71%
- 历史最低 7.20
- 每 手 1
- 风险率 3.53%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy
YD Bio Ltd entered into a definitive Letter of Intent to acquire Safe Save Medical Cell Sciences & Technology Co., Ltd. (SSMC) for approximately US$26.87 million, combining cash and new shares. SSMC specializes in dendritic cell immunotherapy with its ADCTA technology. The acquisition aims to augment YD Bio's R&D capabilities and expand its presence in cell and gene therapies. The deal, subject to customary closing conditions, is expected to clos...
01-29 13:30
YD Bio Strikes Memorandum Of Understanding To Merge With EG BioMed; Financial Terms Not Disclosed
YD Bio Limited ("YD Bio" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the Company has entered
01-06 22:09
YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation–Driven AI Platforms for Cancer Diagnostics and Drug Development
YD Bio Limited has signed a non-binding Memorandum of Understanding (MOU) to merge with EG BioMed, aiming to integrate their DNA methylation-based cancer detection technologies and AI-driven analytics to build a comprehensive oncology platform. The merger could enhance YD Bio's transition into a platform-based biotech company, combining diagnostics, therapeutics, real-world data, and AI for improved cancer detection and treatment. EG BioMed's DNA...
01-06 14:00
YD Bio Announces Latest Plans For New Sites, U.S. Operations Center In California
YD Bio Limited ("YD Bio" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced initiation of its latest
2025-12-16 22:05
Reported Earlier: YD Bio Through Its Partner 3D Global Biotech, Announces Exovisse Contact Lenses Has Obtained FDA 510(k) Clearance As A Class II Medical Device, Enabling Legal Marketing In The U.S.; Its Exovisse Artificial Tears Have Been Developed In Compliance With The FDA OTC Final Monograph M018
YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the Company has reached a
2025-11-25 04:19
YD Bio Announces Its Support For The Global Commercialization Of Okaidx, A Research-Use-Only Blood Test For Post-Treatment Breast Cancer Monitoring
YD Bio Limited ("YD Bio" or the "Company") (NASDAQGM:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced its support for the global
2025-11-05 21:35
YD Bio Ltd. Rings Nasdaq Opening Bell to Celebrate Listing under Ticker YDES
YD Bio Limited rang the Nasdaq Opening Bell to celebrate its public listing, marking a milestone in its journey as a biotechnology company. The listing strengthens its capital base, enhances its global visibility, and accelerates the commercialization of its innovative diagnostic and regenerative medicine platforms. YD Bio, founded in 2013, has evolved from a clinical trial drug supplier to a diversified biotech innovator, leveraging strategic pa...
2025-10-20 14:20
YD Bio Announces CAP Accreditation Of EG Biomed's CLIA-Certified Laboratory, Advancing U.S. Clinical Testing Capabilities
YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that its business partner, EG
2025-10-10 20:39
YD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing Capabilities
YD Bio's partner, EG Biomed, has achieved CAP accreditation for its CLIA-certified laboratory, enhancing its ability to deliver advanced diagnostic tests in the U.S. This milestone strengthens YD Bio's commitment to innovation in cancer detection and ophthalmology. EG Biomed's Chief R&D Officer also presented new findings on a novel biomarker for pancreatic cancer at the AACR conference.
2025-10-10 12:37
YD Bio Limited Reports Unaudited Half Year 2025 Financial Results
YD Bio Limited announced its unaudited financial results for the six months ended June 30, 2025. The company secured $13.2 million to support YD Biopharma's operations following its merger with Breeze Holdings. Despite a 9% net revenue decline to $204,007, YD Biopharma continued investing in R&D and advanced two licensed patents to expand capacity. The top five products accounted for 56% of total revenue, with Keytruda injection being the top ear...
2025-09-30 21:25
